# Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT02101021** · PHASE3 · TERMINATED · sponsor: **Sierra Oncology LLC - a GSK company** · enrollment: 25 (actual)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Momelotinib
- **DRUG:** Placebo to match momelotinib
- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02101021
- **Lead sponsor:** Sierra Oncology LLC - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06-02
- **Primary completion:** 2017-04-10
- **Final completion:** 2017-04-10
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02101021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02101021, "Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02101021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*